Align Summit 2026: Natick based MelliCell is targeting MNK (MAPK-interacting kinase), a genetic switch that could make a difference in fragile X syndrome and beyond
Founder Ben Pope describes the rationale of hitting the target and why he believes a clinical trial in Fragile X could provide evidence of the target's relevance in obesity, Alzheimer's, and more.
Coverage brought to you by










.png)